Clinical Appropriateness Guidelines

Genetic Testing for Hereditary Cancer Susceptibility

EFFECTIVE SEPTEMBER 6, 2021
# Table of Contents

Scope ................................................................................................................................. 3

Genetic Counseling Requirement ........................................................................................ 3

Appropriate Use Criteria .................................................................................................... 4

  Multi-Gene Panel Testing ............................................................................................... 4

  Germline Testing Following Identification of a Somatic Pathogenic or Likely Pathogenic (P/LP)
  Variant ........................................................................................................................... 5

  National Comprehensive Cancer Network® (NCCN®) Criteria* ........................................ 5

  Hereditary Paraganglioma-Pheochromocytoma Syndrome .............................................. 6

  von Hippel-Lindau .......................................................................................................... 6

CPT Codes .......................................................................................................................... 7

Background ........................................................................................................................ 11

  Rationale for Genetic Counseling for Hereditary Cancer Conditions ................................. 12

  Germline testing following identification of a somatic pathogenic or likely pathogenic (P/LP)
  variant ............................................................................................................................ 13

  Hereditary Paraganglioma-Pheochromocytoma Syndrome .............................................. 14

  von Hippel-Lindau .......................................................................................................... 15

Professional Society Guidelines .......................................................................................... 15

Selected References ............................................................................................................ 16

Revision History .................................................................................................................. 18
Scope

This document addresses germline genetic testing for hereditary cancer predisposition syndromes. It does not address somatic tumor testing (see Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies), reproductive testing for hereditary cancer syndromes (see Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis), or polygenic risk scores (see Clinical Appropriateness Guidelines for Genetic Testing for Single-Gene and Multifactorial Conditions). All tests listed in these guidelines may not require prior authorization; please refer to the health plan.

Genetic Counseling Requirement

Genetic testing included in these guidelines is covered when:

1. The patient meets coverage criteria outlined in the guidelines
2. A recommendation for genetic testing has been made by one of the following:
   - An independent board-certified or board-eligible medical geneticist not employed by a commercial genetic testing laboratory*
   - An American Board of Medical Genetics or American Board of Genetic Counseling-certified genetic counselor not employed by a commercial genetic testing laboratory*
   - A genetic nurse credentialed as either a Genetic Clinical Nurse (GCN) or an Advanced Practice Nurse in Genetics (APGN) by either the Genetic Nursing Credentialing Commission (GNCC) or the American Nurses Credentialing Center (ANCC) who is not employed by a commercial genetic testing laboratory*

Who:

- Has evaluated the case and performed pre-test genetic counseling with the patient or the patient’s legal guardian
- Has completed a three-generation pedigree
- Intends to engage in post-test follow-up counseling with the patient or the patient’s legal guardian

*A physician, genetic counselor or genetic nurse employed by a laboratory that operates within an integrated, comprehensive healthcare delivery system is not considered to be an employee of a commercial genetic testing laboratory for the purpose of these guidelines.
Appropriate Use Criteria

Genetic testing for hereditary cancer susceptibility, when the condition is not listed below, is medically necessary when all of the following criteria are met:

- Genetic testing results will impact medical management
- National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) include category 1 or 2A, and/or other published management recommendations for an individual who tests positive for the condition/syndrome-specific genes for which testing is being requested
- The individual is the most appropriate person to test or the most appropriate family member is unavailable for testing
- At least one of the following:
  - Individual or unavailable affected family member meets specific testing criteria for at least one of the syndromes listed below
  - Personal and/or family history is consistent with the hereditary cancer syndrome being tested for when that syndrome is not specifically addressed in these guidelines
- Testing method is as targeted as possible (e.g., single gene, known familial pathogenic or likely pathogenic (P/LP) variant, etc.)
- Testing methodology* has been clinically validated and is the most accurate method unless technical limitations (e.g., poor sample quality) necessitate the need for alternate testing strategies

*The testing methodology may target DNA and/or RNA.

Single-site testing of familial variants of uncertain significance is not medically necessary.

Multi-Gene Panel Testing

If not otherwise specified, multi-gene panel testing for hereditary cancer predisposition syndromes described in these guidelines is medically necessary when all of the following criteria are met:

- Genetic testing results will impact medical management AND
- Individual meets genetic testing criteria, NCCN Guidelines® or other published clinical diagnostic criteria, for at least one hereditary cancer syndrome (e.g., Hereditary Breast and Ovarian Cancer syndrome, Lynch syndrome, Familial Adenomatous Polyposis, von Hippel Lindau, Cowden syndrome, Li-Fraumeni syndrome) AND
- All genes in the panel have peer-reviewed, clinical validity data which have been shown to be associated with the cancer(s) in the personal and/or family history for the individual being tested AND
- There are NCCN Guidelines® category 1 or 2A, and/or other published management recommendations for all genes included in the panel
Testing for genes without established clinical validity (e.g., FANCC, MRE11A, RAD50, RECQL4, RINT1, SLX4, XRCC2, GALNT12, SEMA4A, FAN1, ENG, XRCC4, BUB1, BUB3, PTPRJ, EXO1, PMS1) is not medically necessary.

**Germline Testing Following Identification of a Somatic Pathogenic or Likely Pathogenic (P/LP) Variant**

Germline testing, after a somatic P/LP variant is identified through the evaluation of solid or hematologic malignancy, is medically necessary when all of the following have been met:

- The variant is pathogenic or likely pathogenic
- There are NCCN Guidelines® category 1 or 2A and/or other published management recommendations specific to P/LP variants in the requested gene
- The P/LP variant is not in one of the genes described below

For P/LP variants in genes in which somatic variants are common but corresponding germline variants are rare (e.g., TP53, PTEN, STK11, and APC), testing is considered medically necessary when the first two above criteria and ANY of the following additional criteria are met:

- Individual meets established testing criteria for the associated hereditary cancer syndrome
- The P/LP variant identified has a high rate of germline incidence
- There is high clinical suspicion based on patient or family history or pathogenic/likely pathogenic allele frequency in the tumor sample

**National Comprehensive Cancer Network® (NCCN®) Criteria*\**

Genetic testing for the following syndromes is medically necessary when an individual meets the testing criteria outlined in the relevant NCCN® Clinical Practice Guidelines in Oncology:

- Hereditary Colorectal Cancer Syndromes
  - Hereditary Colorectal Cancer syndromes include: Lynch syndrome, Familial adenomatous polyposis (FAP)/Attenuated familial adenomatous polyposis (AFAP), MYH associated polyposis, Juvenile polyposis syndrome, Peutz-Jeghers syndrome, Serrated Polyposis Syndrome
  - Lynch syndrome related cancers for the purpose of evaluating criteria include: colorectal, endometrial, keratoacanthoma, stomach, ovarian, small bowel, urothelial, sebaceous adenoma or carcinoma, hepatobiliary, pancreas, and brain cancer
  - Testing is for genes as listed in NCCN® Genetic/Familial High-Risk Colorectal Cancer, v1.2020
- Hereditary Breast and Ovarian Cancer Syndromes
  - Hereditary Breast and Ovarian Cancer syndromes include: Hereditary Breast and Ovarian Cancer syndrome, Cowden syndrome/PTEN Hamartoma tumor syndrome, Li Fraumeni syndrome, and other breast/ovarian cancer susceptibility syndromes
o Hereditary breast and ovarian cancer syndromes related cancers for the purpose of evaluating criteria include: breast, ovarian, pancreatic and prostate cancer.

o Testing is for susceptibility genes (high and moderate penetrant genes) as listed in NCCN® Genetic/Familial High-Risk Breast, Ovarian and Pancreatic, v.2.2021

- Multiple Endocrine Neoplasia (type 1 and type 2)
  o Testing is for genes as listed in NCCN® Neuroendocrine and Adrenal Tumors, v2.2020

- Diffuse Gastric Cancer
  o Testing is for genes as listed in NCCN® Gastric Cancer, v1.2021

**Hereditary Paraganglioma-Pheochromocytoma Syndrome**

Single gene testing or a targeted gene panel is medically necessary for hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome when all of the following criteria are met:

- Individual meets general criteria for hereditary cancer genetic testing (above)
- Individual* with pheochromocytoma or paraganglioma
- Other syndromes and causes of PGL/PCC have been ruled out (e.g., multiple endocrine neoplasia)

*Testing can be extended to first- or second- degree relatives if the affected proband is unavailable for testing.

Single-site testing is medically necessary for those at risk for a known familial deleterious P/LP variant.

**von Hippel-Lindau**

Genetic testing is medically necessary for von Hippel-Lindau (VHL) syndrome when an individual meets general criteria for hereditary cancer genetic testing (above) and any one of the following indications:

- At risk individual from a family with a known familial VHL P/LP variant
- Retinal angioma/hemangioblastoma, especially in a young patient
- Spinal or cerebellar hemangioblastoma
- Adrenal or extra-adrenal pheochromocytoma
- Renal cell carcinoma, if the patient is under age 47 years or has a personal or family history of any other tumor typical of VHL
- Multiple renal and pancreatic cysts
- Neuroendocrine tumors of the pancreas
- Endolymphatic sac tumors
- Multiple papillary cystadenomas of the epididymis or broad ligament

CPT Codes

The following codes are associated with the guidelines in this document. This list is not all inclusive. Medical plans may have additional coverage policies that supersede these guidelines.

Covered when medical necessity criteria are met:

81162  BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis (ie, detection of large gene rearrangements)

81163  BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis

81164  BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)

81165  BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis

81166  BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)

81167  BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)

81201  APC (adenomatous polyposis coli) (eg, familial adenomatous polyposis [FAP], attenuated FAP) gene analysis; full gene sequence

81202  APC (adenomatous polyposis coli) (eg, familial adenomatous polyposis [FAP], attenuated FAP) gene analysis; known familial variants

81203  APC (adenomatous polyposis coli) (eg, familial adenomatous polyposis [FAP], attenuated FAP) gene analysis; duplication/deletion variants

81212  BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81215</td>
<td>BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant</td>
</tr>
<tr>
<td>81216</td>
<td>BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis</td>
</tr>
<tr>
<td>81217</td>
<td>BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant</td>
</tr>
<tr>
<td>81288</td>
<td>MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; promoter methylation analysis</td>
</tr>
<tr>
<td>81292</td>
<td>MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis</td>
</tr>
<tr>
<td>81293</td>
<td>MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants</td>
</tr>
<tr>
<td>81294</td>
<td>MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants</td>
</tr>
<tr>
<td>81295</td>
<td>MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis</td>
</tr>
<tr>
<td>81296</td>
<td>MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants</td>
</tr>
<tr>
<td>81297</td>
<td>MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants</td>
</tr>
<tr>
<td>81298</td>
<td>MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis</td>
</tr>
<tr>
<td>81299</td>
<td>MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants</td>
</tr>
<tr>
<td>81300</td>
<td>MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants</td>
</tr>
<tr>
<td>81307</td>
<td>PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence</td>
</tr>
<tr>
<td>Gene</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>PALB2</td>
<td>partner and localizer of BRCA2 (eg, breast and pancreatic cancer)</td>
</tr>
<tr>
<td>PMS2</td>
<td>post meiotic segregation increased 2 [S. cerevisiae] (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome)</td>
</tr>
<tr>
<td>PMS2</td>
<td>post meiotic segregation increased 2 [S. cerevisiae] (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome)</td>
</tr>
<tr>
<td>PMS2</td>
<td>post meiotic segregation increased 2 [S. cerevisiae] (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome)</td>
</tr>
<tr>
<td>PTEN</td>
<td>phosphatase and tensin homolog (eg, Cowden syndrome, PTEN hamartoma tumor syndrome)</td>
</tr>
<tr>
<td>PTEN</td>
<td>phosphatase and tensin homolog (eg, Cowden syndrome, PTEN hamartoma tumor syndrome)</td>
</tr>
<tr>
<td>PTEN</td>
<td>phosphatase and tensin homolog (eg, Cowden syndrome, PTEN hamartoma tumor syndrome)</td>
</tr>
<tr>
<td>TP53</td>
<td>tumor protein 53 (eg, Li-Fraumeni syndrome)</td>
</tr>
<tr>
<td>TP53</td>
<td>tumor protein 53 (eg, Li-Fraumeni syndrome)</td>
</tr>
<tr>
<td>TP53</td>
<td>tumor protein 53 (eg, Li-Fraumeni syndrome)</td>
</tr>
<tr>
<td>TP53</td>
<td>tumor protein 53 (eg, Li-Fraumeni syndrome)</td>
</tr>
<tr>
<td>Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, and TP53</td>
<td>Gene panel</td>
</tr>
<tr>
<td>Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11</td>
<td>Gene panel</td>
</tr>
<tr>
<td>Hereditary colon cancer syndromes (eg, Lynch syndrome, familial adenomatous polyposis); genomic sequence analysis panel, must include analysis of at least 7 genes, including APC, CHEK2, MLH1, MSH2, MSH6, MUTYH, and PMS2</td>
<td>Gene panel</td>
</tr>
</tbody>
</table>
81436 Hereditary colon cancer syndromes (eg, Lynch syndrome, familial adenomatous polyposis); duplication/deletion gene analysis panel, must include analysis of at least 8 genes, including APC, MLH1, MSH2, MSH6, PMS2, EPCAM, CHEK2, and MUTYH

81437 Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); genomic sequence analysis panel, must include sequencing of at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127, and VHL

81438 Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL

0129U Hereditary breast cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication analysis panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53)

Codes that do not meet medical necessity criteria:

0101U Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatous polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])

0102U Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNA analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])

0103U Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNA analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], EPCAM [deletion/duplication only])

0130U-0138U +RNAInsight™ (Ambry Genetics®)

0157U APC (APC regulator of WNT signaling pathway) (eg, familial adenomatosis polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure) (Use 0157U in conjunction with 81201)
Background

Cancer is the result of genetic alterations that often result in the deregulation of pathways that are important for various cellular functions including growth, cell cycle progression, and apoptosis (programmed cell death), among others. While most genetic P/LP variants identified within a tumor are acquired, there are several cancer predisposition syndromes caused by inherited germline P/LP
variants. Many of these, such as Hereditary Breast and Ovarian Cancer Syndrome associated with BRCA1 and BRCA2, are well-described with consensus recommendations for genetic testing and management. Others, however, have been recently identified and testing criteria and management recommendations are not well established.

See relevant NCCN Guidelines® for background related to Lynch syndrome, Familial adenomatous polyposis (FAP)/Attenuated familial adenomatous polyposis (AFAP), MYH-associated polyposis, Hereditary breast, ovarian, and pancreatic cancer susceptibility syndromes, Juvenile polyposis syndrome, Peutz-Jeghers syndrome, Cowden syndrome/PTEN Hamartoma tumor syndrome, Li Fraumeni syndrome, Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia type 2 (MEN2A and 2B), and Diffuse gastric cancer.

Rationale for Genetic Counseling for Hereditary Cancer Conditions

Pre-test genetic counseling provides individuals seeking genetic testing the opportunity to make informed decisions about their genetic testing and subsequent medical management options. Genetic counseling combines expertise in obtaining and interpreting family history information, the ability to identify the most beneficial individual in a family to initiate testing, identification of the most appropriate testing options, experience in obtaining informed consent for testing and proficiency in genetic variant interpretation, in order to maximize the genetic testing experience for patients and their healthcare providers. The genetic counseling informed consent process also educates and empowers patients to consider the psychological, financial, employment, disability, and insurance implications of genetic testing and results (Al-Khatib et al. 2018). Patients who receive genetic counseling report increased knowledge, understanding, and satisfaction regarding their genetic testing experience (Armstrong et al. 2015; Harvey et al. 2007).

The advent of multi-gene panels and genome-scale sequencing have increased the complexity of the genetic testing landscape. Misuse of genetic testing increases the risk for adverse events and patient harm, including missed opportunities for diagnosis and disease prevention (Bellcross et al. 2011; Plon et al. 2011; Farmer et al. 2019). Genetic information requires expert interpretation and ongoing re-evaluation to ensure the most accurate interpretation is utilized to inform medical management decision making. The multitude of genetic testing options as well as the complex information revealed by genetic testing can make choosing the most appropriate test and interpretation of results difficult for non-genetics healthcare providers (Ray 2011). Involvement of a clinical genetics provider has been shown to ensure the correct test is ordered, limit result misinterpretation and allow patients to make informed, evidence-based medical decisions with their healthcare providers (Cragun et al. 2015; Farmer et al. 2019).

Genetic counseling not only improves patient outcomes but also reduces unnecessary healthcare spending. Pre-test genetic counseling has been shown to reduce inappropriate test ordering and prevent unnecessary medical procedures and interventions that follow from inaccurate result interpretation (DHHS 2011). While genetic testing is now available for almost all clinical specialties, correct use and interpretation is necessary to prevent adverse outcomes. While genetic counseling may benefit any patient considering or undergoing genetic testing, tests that offer predictive information or have a higher chance of identifying variants of uncertain significance often carry stronger recommendations in the form of consensus guidelines and professional statements recommending genetic counseling by trained genetics professionals.

Many consensus organizations including the American Society of Clinical Oncology (ASCO) (Robson et al. 2015), the National Comprehensive Cancer Network® (NCCN®) * the American College of
Obstetricians and Gynecologists (ACOG 2017) and the U.S. Preventive Services Task Force (USPSTF) (Moyer 2014) recommend genetic counseling as an integral part of the evaluation of individuals at risk for hereditary cancer susceptibility syndromes. Additionally, the Patient Protection and Affordable Care Act (2010) has established that counseling prior to P/LP variant testing is an established essential health benefit appropriate for individuals with breast cancer.

Per the NCCN®, cancer risk assessment and genetic counseling by a cancer genetics professional is highly recommended when genetic testing is offered (ie, pre-test counseling) and after results are disclosed (ie, post-test counseling), with assurance that the pre-test counseling includes collection of a comprehensive family history, evaluation of risk, full genetic differential review and education for the patient on the outcomes of testing, as well as full informed consent.

The American Society of Clinical Oncologists (ASCO) (Robson et al. 2015) additionally recognizes that multi-gene testing for hereditary cancer susceptibility is currently challenged by uncertainties and areas of needed study, and thus recommend that this testing is ideally handled by providers who are well educated on the complex nature of this genetic testing. Additional note is made that evidence has suggested that overinterpretation of variants identified in these panels by non-expert providers may harm patient care, such as inappropriate medical interventions and psychological stress. Thus, since 1996 ASCO has recommended that pre-test counseling for hereditary predisposition testing includes, at minimum: details on the purpose of testing, potential outcomes, implications for the patient and their family members, risks associated with the genes being tested, costs associated, psychological implications, risks and protections for genetic discrimination, confidentiality issues related to genetic testing, research use of samples, alternate options to testing, utility of medical surveillance and prevention, importance of sharing results with at risk relatives, follow up planning for results, rate of variants of uncertain significance, as well as contrast of high penetrance to low penetrance genes. While steps are being made to improve knowledge gaps, ASCO recognizes that the level of knowledge of genetics needed by oncologists “exceeds what most received during training.” Because of the complex nature of germline genetic testing (both targeted and panel-based), and the time required for these discussions, ASCO states “it is particularly important that providers with particular experience in the assessment of inherited cancer risk be involved in the ordering and interpretation of these tests.”

**Germline testing following identification of a somatic pathogenic or likely pathogenic (P/LP) variant**

As tumor testing, especially broad molecular profiling, becomes more common, it is expected that there will be an increase in the number of somatic P/LP variants identified in genes associated with hereditary cancer syndromes. In most cases, this is associated with a risk that a germline P/LP variant will be identified, but with certain cancer types and genes, the likelihood of an underlying germline P/LP variant remains low. In addition, many types of tumors have a high rate of variation in genes associated with hereditary cancer syndromes, but unrelated to the same tumor type. An often-cited example of this is the high-rate of APC P/LP variants identified in endometrial cancer, despite the fact that germline P/LP variants in APC are not associated with an increased risk of endometrial cancer (Jain et al. 2016). In a recent statement from the American College of Medical Genetics, it is affirmed that there is insufficient evidence to inform “best practices” for reporting presumed germline pathogenic variants (PGPVs) when tumor testing is performed (Li et al. 2020). It is acknowledged that evidence is emerging in support of an analysis pipeline for tumor testing that is designed to identify PGPVs. However, it is also noted that tumor-normal paired testing is not a replacement for dedicated germline genetic testing given that not all PGPVs will be identified with this approach (Li et al. 2020).
Several studies have shown that the prevalence of pathogenic germline variants among those in whom somatic variants have been identified is high enough to consider germline testing in most actionable genes (Catenacci et al. 2015; Schrader et al. 2016). One of the largest studies to date, using the Foundation Medicine platform, predicted that variants in high-risk cancer genes were likely pathogenic or pathogenic in 3.1 to 7% of tumor samples tested; however, the study design did not compare the tumor DNA to normal. Additionally, this study noted the rate of germline P/LP variants varies widely by tissue type and gene (Hall 2015). It has been noted that identification of TP53, STK11, PTEN and APC in tumor tissue are less likely to be associated with germline P/LP variants (Jain et al. 2016). For instance, TP53 variants are identified in almost 85% of ovarian tumors (COSMIC data), but fewer than 3% of patients with apparently hereditary ovarian cancer syndromes will test positive for a TP53 P/LP variant. Therefore, additional factors, such as clinical presentation, family history, or data obtained from variant databases regarding likelihood of a germline origin should be considered when determining medical necessity of germline testing for these actionable genes.

Hereditary Paraganglioma-Pheochromocytoma Syndrome

Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues symmetrically distributed along the paravertebral axis from the base of the skull to the pelvis) and by pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base, neck, and upper mediastinum; approximately 95% of such tumors are non-secretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically hypersecrete catecholamines.

Up to half of all patients with PGL/PCC have an inherited germline P/LP variant in a gene known to predispose to these tumor types, therefore hereditary syndromes should be considered in all individuals with paragangliomas and/or pheochromocytomas (Young 2011; Lenders et al. 2014; Fishbein et al. 2013; Toledo et al. 2017; Buffett et al. 2019; Muth et al. 2019). Individuals with a young age of onset, multiple, bilateral, recurrent, or multifocal tumors have a particularly high chance of a hereditary cause.

P/LP variants in over 15 genes are reported to cause hereditary PCC/PGL syndromes, which are most frequently inherited in an autosomal dominant manner, although with incomplete penetrance. The genes most commonly associated with hereditary PCC/PGL are the succinate dehydrogenase genes (SDHA, SDHB, SDHC, SDHD, and SDHAF2 (sometimes referred to as SDH5)). TMEM127, FH, and MAX are other genes that have been described in cases of hereditary PGL/PCC (Eisenhofer et al. 2017; Castro-Vega et al. 2014; Clark et al. 2014). In addition, there are other known hereditary cancer syndromes in which pheochromocytomas may occur. If there are clinical signs of these conditions, genetic testing should be considered based on the recommended guidelines for the suspected condition. When the presentation does not appear to be syndromic, then family history, tumor location, and/or biochemical phenotype may be helpful in guiding genetic testing. Targeted panels for nonsyndromic PCC/PGL genes may also be appropriate (Lenders et al. 2014; Gupta and Pacak 2017; Eisenhofer et al. 2017; Else et al. 2018). Presymptomatic genetic testing for relatives who are eligible for screening should be based on the degree of relation and inheritance pattern (Muth et al. 2019). Genetic testing may improve clinical outcomes by increasing adherence to surveillance and management recommendations (Buffet et al. 2019).
von Hippel-Lindau

Von Hippel-Lindau (VHL) disease is characterized by abnormal growth of blood vessels, which can lead to hemangioblastomas of the brain, spinal cord and retinas; renal cysts and clear cell renal carcinomas; pheochromocytomas; and endolymphatic sac tumors. P/LP variants in the VHL gene are inherited in an autosomal dominant manner. It is estimated that 80% of individuals with VHL inherited it from an affected parent, and approximately 20% are due to new or de novo P/LP variants (van Leeuwaarde et al. 2019).

Although clinical diagnosis is possible, molecular confirmation is recommended to confirm the diagnosis in patients not fully meeting diagnostic criteria and to facilitate screening in asymptomatic/pre-symptomatic relatives, including at-risk children (Nielsen et al. 2016).

Professional Society Guidelines

American College of Obstetricians and Gynecologists (ACOG)


American College of Medical Genetics and Genomics (ACMG)


American Society of Clinical Oncology (ASCO)

Endocrine Society

International Gastric Cancer Linkage Consortium (IGCLC)

Joint Statements
**NCCN® Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © 2021 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN® website: http://www.nccn.org/index.asp.**


The NCCN Guidelines® are a work in progress that may be refined as often as new significant data becomes available.

The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

**Selected References**

Young WF Jr, Abboud AL. Editorial: paraganglioma
2006; 295:1379


Revision History

Medical Advisory Board Review:

v2.2021 03/12/2021: Approved
v1.2021 11/13/2020: Approved
v3.2020 11/13/2020: Approved
v2.2020 05/08/2020: Reviewed
v1.2020 11/04/2019: Approved

GUIDELINES

v1.2020

v3.2020

v2.2021

Reserved.

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2021 Informed Medical Decisions, Inc. All Rights Reserved.

v0.2019
v2.2019 05/23/2019: No Criteria Changes
v1.2018 03/31/2018: Reviewed

Clinical Steering Committee Review:

v2.2021 02/22/2021: Approved
v1.2021 10/13/2020: Approved
v3.2020 10/13/2020: Approved
v2.2020 04/06/2020: Approved
v1.2020 10/11/2019: Approved
v2.2019 05/20/2019: Approved
v1.2019 10/03/2018: Approved
v1.2018 02/28/2018: Approved
v3.2017 11/01/2017: Approved
v2.2017 05/03/2017: Approved
v1.2017 01/25/2017: Approved

Revisions:

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Editor</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>v2.2021</td>
<td>02/22/2021</td>
<td>Eleanor Riggs, MS, CGC</td>
<td>Semi-annual review. PGL/PCC and VHL criteria were clarified. NCCN Guidelines® Gastric Cancer v1.2021 was updated. Updated CPT codes, professional society guidelines, background and references.</td>
</tr>
<tr>
<td>v1.2021</td>
<td>9/11/2020</td>
<td>Stefanie Finch, MS, CGC and Eleanor Riggs, MS, CGC</td>
<td>Semi-annual review. Genetic counseling requirements were updated. Reformatted NCCN® criteria. Updated CPT codes, professional society guidelines, background and references.</td>
</tr>
<tr>
<td>v3.2020</td>
<td>10/9/2020</td>
<td>Eleanor Riggs, MS, CGC</td>
<td>Interim Update: NCCN Guidelines® Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2021) was updated. CPT codes were updated.</td>
</tr>
<tr>
<td>Version</td>
<td>Date</td>
<td>Reviewer</td>
<td>Notes</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>---------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>v2.2020</td>
<td>03/13/2020</td>
<td>Eleanor Riggs, MS, CGC</td>
<td>Semi-annual review. The Multi-Gene Panel Testing criteria was updated, i.e., removal of MSH3 from the list of genes without established clinical validity. Removed CHEK2, PALB2 and prostate cancer criteria. Updated professional society guidelines, background and references.</td>
</tr>
<tr>
<td></td>
<td>07/24/2020</td>
<td>Carrie Langbo, MS, CGC</td>
<td>NCCN Guidelines® were accessed for inclusion of the most recent published version.</td>
</tr>
<tr>
<td>v1.2020</td>
<td>09/11/2019</td>
<td>Eleanor Riggs, MS, CGC</td>
<td>Semi-annual review. Revisions were made to multi-gene panel testing criteria, corrections were made to CHEK2 and PALB2 criteria and Prostate Cancer criteria was updated. CPT codes, background, Professional Society/NCCN® guidelines and references were updated.</td>
</tr>
<tr>
<td></td>
<td>2/5/2020</td>
<td>Carrie Langbo, MS, CGC</td>
<td>NCCN Guidelines® were accessed for inclusion of the most recent published version. Minor revisions to text were incorporated based on updated Guidelines but did not impact coverage criteria/necessitate MAB/CSC review.</td>
</tr>
<tr>
<td>v3.2019</td>
<td>12/9/2019</td>
<td>Carrie Langbo, MS, CGC</td>
<td>Interim Update: Revisions made to multi-gene panel testing criteria and approved by the PAB on 11/04/2019 and the CSC on 10/11 and 12/09/2019 are being published as an interim update, prior to the anticipated March 3, 2020 effective date, in order to accommodate recent revisions to NCCN® Guideline, Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic (v1.2020).</td>
</tr>
<tr>
<td>v2.2019</td>
<td>05/17/2019</td>
<td>Michele Gabree, MS, CGC</td>
<td>Semi-annual review. No criteria changes. Text clarification made for prostate cancer germline testing. Updated references.</td>
</tr>
<tr>
<td></td>
<td>07/25/2019</td>
<td>Carrie Langbo, MS, CGC</td>
<td>NCCN Guidelines® were accessed for inclusion of the most recent published version. Minor revisions to text were incorporated based on updated Guidelines but did not impact coverage criteria/necessitate MAB/CSC review.</td>
</tr>
</tbody>
</table>

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2015-2021 Informed Medical Decisions, Inc. All Rights Reserved.
<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Author</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>v2.2017</td>
<td>07/03/2017</td>
<td>Denise Jones, MS, CGC</td>
<td>Quarterly review. No criteria changes. Updated references.</td>
</tr>
<tr>
<td>v2.2017</td>
<td>05/03/2017</td>
<td>Gwen Fraley, MS, CGC</td>
<td>Expanded PGL/PCC criteria to include panels. Updated references.</td>
</tr>
<tr>
<td>Version</td>
<td>Date</td>
<td>Author</td>
<td>Notes</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>------------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>v1.2016</td>
<td>05/24/2016</td>
<td>Marie Schuetzle, MS, CGC</td>
<td>Added PALB2 and CHEK2 criteria. Updated references.</td>
</tr>
<tr>
<td>v1.2015</td>
<td>05/07/2015</td>
<td>Marie Schuetzle, MS, CGC</td>
<td>Original version</td>
</tr>
</tbody>
</table>

**Original Effective Date:** 05/07/2015

**Primary Author:** Marie Schuetzle, MS, CGC